Health & Beauty

According to the news from the media briefing held by China Sinopharm Group on the 15th, Sinopharm Group's China Bio-New Crown Vaccine has been approved for registration or emergency use in 119 countries, regions and international organizations, and the vaccinated population covers 196 countries. Production and supply of 3.5 billion doses of the new crown vaccine.

China Sinopharm Group held a media briefing on the same day to introduce the progress of its Chinese biological new crown vaccine in the field of international cooperation. Liu Jingzhen, Secretary of the Party Committee and Chairman of Sinopharm Group, said that in order to establish a broader immune barrier around the world, Sinopharm Group will do its best to supply vaccines to the world while meeting the domestic demand for vaccines.

According to him, Sinopharm's China Bio-New Crown Vaccine has been approved for registration or emergency use in 119 countries, regions and international organizations. The vaccinated population covers 196 countries, and 3.5 billion doses of the new crown vaccine are produced and supplied at home and abroad.

In addition, in order to bridge the "immunization gap", Sinopharm Group has made every effort to promote the localized production of vaccines in the United Arab Emirates, Serbia, Morocco, Myanmar and other countries, benefiting local people with products and services, and at the same time helping to cultivate local production, quality engineering construction and biosafety. talent.

Zhu Jingjin, Secretary of the Party Committee and Vice President of Sinopharm Group, said that the jointly constructed vaccine production base is expected to become a preparation, storage and distribution center for the new crown vaccine and other vaccines in the United Arab Emirates and even the Middle East after the construction of the vaccine production base is expected to be completed within this year; the first Chinese vaccine in Europe The factory is also under intense construction in Belgrade, Serbia, and the products will meet the needs of Serbia and neighboring countries; in Morocco and Myanmar, vaccine sub-packaging has been carried out smoothly, and the new crown inactivated vaccine has entered thousands of households.

Serbian Ambassador to China Stefanovic said on the same day that the new crown vaccine produced by Sinopharm Group has become a powerful tool in the global fight against the epidemic. "The name of Sinopharm Group is very famous in Serbia. It is not only a symbol of health, but also a symbol of the fight against the new crown epidemic, but also a symbol of steel-like friendship, mutual understanding and support between the two countries. The vaccine production plant built in Belgrade, the capital of Serbia, is expected to It will be put into production soon, and the cooperation will be further deepened in the future.”